Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

Human Gene Therapy

Volumn 14, Issue 3, 2003, Pages 227-241

  Kubo, Hiroyuki ^a,d   Gardner, Thomas A ^b,d   Wada, Yoshitaka ^c   Koeneman, Kenneth S ^d   Gotoh, Akinobu ^c   Yang, Ling ^d   Kao, Chinghai ^b,d   Lim, So Dug ^a   Amin, Mahul B ^a   Yang, Hua ^d   Black, Margaret E ^e   Matsubara, Shigeji ^a,d   Nakagawa, Masayuki ^f   Gillenwater, Jay Y ^d   Zhau, Haiyen E ^a,d   Chung, Leland W K ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e WASHINGTON STATE UNIVERSITY   (United States)

^f KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR CARRYING OSTEOCALCIN PROMOTER DRIVEN HERPES SIMPLEX VIRUS THYMIDINE KINASE; CD4 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; OSTEOCALCIN; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS RECEPTOR;

ADULT; AGED; ANDROGEN BLOOD LEVEL; APOPTOSIS; ARTHRALGIA; ARTICLE; B LYMPHOCYTE ACTIVATION; BACKACHE; BONE MATRIX; BONE METASTASIS; CANCER LOCALIZATION; CANCER RECURRENCE; CELL DEATH; CHILL; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; EDEMA; ENZYME ASSAY; ENZYME LOCALIZATION; FEVER; GENE CONSTRUCT; GENETIC TRANSDUCTION; HEADACHE; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HORMONE DEPENDENCE; HORMONE RESISTANCE; HORMONE RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; ISCHIALGIA; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; METASTASIS; MORPHOLOGICAL TRAIT; MUSCLE WEAKNESS; MYALGIA; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; NICK END LABELING; NOSE CONGESTION; OSTEOBLAST; PAIN ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PREVALENCE; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; STROMA CELL; SYMPTOMATOLOGY; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOCALCIN; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE;

ADENOVIRIDAE; SIMPLEXVIRUS;

EID: 0037429003     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340360535788     Document Type: Article

References (42)

1. AYALA, G., WHEELER, T.M., SHALEV, M., THOMPSON, T.C., MILES, B., AGUILAR-CORDOVA, E., CHAKRABORTY, S., and KADMON, D. (2000). Cytopathic effect of in situ gene therapy in prostate cancer. Hum. Pathol. 31, 866-870.
2. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURTJONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
3. BLACK, M.E., NEWCOMB, T.G., WILSON, H.M., and LOEB, L.A. (1996). Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93, 3525-3529.
4. CHEON, J., KO, S.C., GARDNER, T.A., SHIRAKAWA, T., GOTOH, A., KAO, C., and CHUNG, L.W. (1997). Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 4, 359-365.
5. CHUNG, L.W., GLEAVE, M.E., HSIEH, J.T., HONG, S.J., and ZHAU, H.E. (1991). Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surv. 11, 91-121.
6. CHUNG, L.W., LAW, A., RHEE, H., MATSUBARA, S., HSIEH, C.L., EGAWA, M., PARK, M.S., KOENEMAN, K., YEUNG, F., and ZHAU, H.E. (2003). A novel gene therapeutic strategy co-targeting tumor epithelium and stroma. In Disorders of the Prostate F. Habib and M. Briley, eds. (Martin Dunitz, London) (in press).
7. GARDNER, T.A., KO, S.C., KAO, C., SHIRAKAWA, T., CHEON, J., GOTOH, A., WU, T.T., SIKES, R.A., ZHAU, H.E., CUI, Q., BALIAN, G., and CHUNG, L.W.K. (1998). Exploiting stromal-epithelial interaction for model development and new strategies of gene therapy for prostate cancer and osteosarcoma metastases. Gene Ther. Mol. Biol. 2, 41-58.
8. GLEAVE, M., HSIEH, J.T., GAO, C.A., VON ESCHENBACH, A.C., and CHUNG, L.W. (1991). Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51, 3753-3761.
9. GRAHAM, M.C., SCHER, H.I., LIU, G.B., YEH, S.D., CURLEY, T., DAGHIGHIAN, F., GOLDSMITH, S.J., and LARSON, S.M. (1999). Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin. Cancer Res. 5, 1307-1318.
10. HALL, S.J., MUTCHNIK, S.E., CHEN, S.H., WOO, S.L., and THOMPSON, T.C. (1997). Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int. J. Cancer 70, 183-187.
11. HALL, S.J., SANFORD, M.A., ATKINSON, G., and CHEN, S.H. (1998). Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 58, 3221-3225.
12. HAYNES, P., LAMBERT, T.R., and MITCHELL, I.D. (1996). Comparative in-vivo genotoxicity of antiviral nucleoside analogues: Penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat. Res. 369, 65-74.
13. HEIDENREICH, A., HOFMANN, R., and ENGELMANN, U.H. (2001). The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. 165, 136-140.
14. HIDAKA, C., MILANO, E., LEOPOLD, P.L., BERGELSON, J.M., HACKETT, N.R., FINBERG, R.W., WICKHAM, T.J., KOVESDI, I., ROELVINK, P., and CRYSTAL, R.G. (1999). CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103, 579-587.
15. 3 in androgen-independent human prostate cancer cells and tumors. Cancer Res. 62, 3084-3092.
16. JEMAL, A., THOMAS, A., MURRAY, T., and THUN, M. (2002). Cancer statistics, 2002. CA Cancer J. Clin. 52, 23-47.
17. KIRKMAN, W., III, CHEN, P., SCHROEDER, R., FENELEY, M.R., RODRIGUEZ, R., WICKHAM, T.J., KING, C.R., and BRUDER, J.T. (2001). Transduction and apoptosis induction in the rat prostate, using adenovirus vectors. Hum. Gene Ther. 12, 1499-1512.
18. KO, S.C., CHEON, J., KAO, C., GOTOH, A., SHIRAKAWA, T., SIKES, R.A., KARSENTY, G., and CHUNG, L.W. (1996). Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 56, 4614-4619.
19. KOENEMAN, K.S., YEUNG, F., and CHUNG, L.W. (1999). Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39, 246-261.
20. KOENEMAN, K.S., KAO, C., KO, S.C., YANG, L., WADA, Y., KALLMES, D.F., GILLENWATER, J.Y., ZHAU, H.E., CHUNG, L.W., and GARDNER, T.A. (2000). Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 18, 102-110.
21. LANDSTROM, M., and FUNA, K. (1997). Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages. Int. J. Cancer 71, 451-455.
22. LEE, C.K., AEPPLI, D.M., UNGER, J., BOUDREAU, R.J., and LEVITT, S.H. (1996). Strontium-89 chloride (Metastron) for palliative treatment of bony metastases: The University of Minnesota experience. Am. J. Clin. Oncol. 19, 102-107.
23. LI, Y., PONG, R.C., BERGELSON, J.M., HALL, M.C., SAGALOWSKY, A.I., TSENG, C.P., WANG, Z., and HSIEH, J.T. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330.
24. MATSUBARA, S., WADA, Y., GARDNER, T.A., EGAWA, M., PARK, M.S., HSIEH, C.L., ZHAU, H.E., KAO, C., KAMIDONO, S., GILLENWATER, J.Y., and CHUNG, L.W. (2001). A conditional replication-competent adenoviral vector, Ad-OC-Ela, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 61, 6012-6019.
25. MILES, B.J., SHALEV, M., AGUILAR-CORDOVA, E., TIMME, T.L., LEE, H.M., YANG, G., ADLER, H.L., KERNEN, K., PRAMUDJI, C.K., SATOH, T., GDOR, Y., REN, C., AYALA, G., WHEELER, T.M., BUTLER, E.B., KADMON, D., and THOMPSON, T.C. (2001). Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12, 1955-1967.
26. MILLER, C.R., BUCHSBAUM, D.J., REYNOLDS, P.N., DOUGLAS, J.T., GILLESPIE, G.Y., MAYO, M.S., RABEN, D., and CURIEL, D.T. (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58, 5738-5748.
27. NELSON, J.B., NGUYEN, S.H., WU-WONG, J.R., OPGENORTH, T.J., DIXON, D.B.., CHUNG, L.W., and INOUE, N. (1999). New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53, 1063-1069.
28. OKEGAWA, T., LI, Y., PONG, R.C., BERGELSON, J.M., ZHOU, J., and HSIEH, J.T. (2000). The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. 60, 5031-5036.
29. OKEGAWA, T., PONG, R.C., LI, Y., BERGELSON, J..M., SAGALOWSKY, A.I., and HSIEH, J.T. (2001). The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: A functional analysis of car protein structure. Cancer Res. 61, 6592-6600.
30. PAPAPOULOS, S.E., HAMDY, N.A., and VAN DER PLUIJM, G. (2000). Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 88, 3047-3053.
31. RAMESH, R., MUNSHI, A., MARROGI, A.J., and FREEMAN, S.M. (1999). Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int. J. Cancer 80, 380-386.
32. RAUEN, K.A., SUDILOVSKY, D., LE, J.L., CHEW, K.L., HANN, B., WEINBERG, V., SCHMITT, L.D., and MCCORMICK, F. (2002). Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res. 62, 3812-3818.
33. SCHER, H.I., and KELLY, W.K. (1993). Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11, 1566-1572.
34. SHIRAKAWA, T., KO, S.C., GARDNER, T.A., CHEON, J., MIYAMOTO, T., GOTOH, A., CHUNG, L.W., and KAO, C. (1998). In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther. 5, 274-280.
35. STEPHENSON, J. (2001). Experimental prostate cancer drugs slow disease progression. JAMA 286, 34.
36. SZOSTAK, M.J., and KYPRIANOU, N. (2000). Radiation-induced apoptosis: Predictive and therapeutic significance in radiotherapy of prostate cancer [review]. Oncol. Rep. 7, 699-706.
37. TOMKO, R.P., XU, R., and PHILIPSON, L. (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 94, 3352-3356.
38. TONG, X.W., ENGEHAUSEN, D.C., KAUFMAN, R.H., AGOULNIK, I., CONTANT, C., FREUND, C.T., OEHLER, M.K., KIM, T.E., HASENBURG, A., WOO, S.L, and KIEBACK, D.C. (1998). Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy. Anticancer Res. 18, 713-718.
39. TU, S.M., MILLIKAN, R.E., MENGISTU, B., DELPASSAND, E.S., AMATO, R.J., PAGLIARO, L.C., DALIANI, D., PAPANDREOU, C.N., SMITH, T.L., KIM, J., PODOLOFF, D.A., and LOGOTHETIS, C.J. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 357, 336-341.
40. TURNER, S.L., GRUENEWALD, S., SPRY, N., and GEBSKI, V. (2001). Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br. J. Cancer 84, 297-302.
41. WANG, X., and BERGELSON, J.M. (1999). Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. J. Virol. 73, 2559-2562.
42. WU, H.C., HSIEH, J.T., GLEAVE, M.E., BROWN, N.M.., PATHAK, S., and CHUNG, L.W. (1994). Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int. J. Cancer 57, 406-412.